Figure 3.

Epigenetic therapy with 5-aza-dC and TSA synergistically inhibits breast tumor growth in mice. (A) Experimental schemes of the tumor therapy. Mice bearing 4T1 or 4T1-luc tumors (approximately 100–150 mm³ in size) in the left and lower mammary gland were treated with 5-aza-dC and TSA, alone or in combination (1 mg/kg body weight 5-aza-dC and 0.3 mg/kg body weight TSA, once a day, for 5 d), at 2 weeks after tumor inoculation. (B) Whole-body bioluminescence images of mice bearing 4T1-luc tumors were taken 10 min after injection of D-luciferin into the mice after treatments. Scale bar represents the intensity of luminescence. (C) Quantitation of the total photon flux (the number of photons per second, p/s) obtained upon whole-body imaging. Data have been presented as the mean ± S.D. ***, P<0.001; n.s., not significant (n=5 per group), as assessed using two-way ANOVA. (D–G) Tumor volumes (D), body weight (E), number of metastatic nodules in the lung (F), and survival rates (G) after treatments. Data have been presented as the mean ± S.D. *, P<0.05; ***, P<0.001; n.s., not significant (n=10 mice per group), as assessed using one-way ANOVA followed by Tukey’s multiple comparison post-hoc test.